Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Head and neck cancer highlights at ASCO 2021

Ari Rosenberg, MD, University of Chicago Medicine, Chicago, IL, discusses the highlights concerning head and neck cancer from the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting. Treatment with gemcitabine, cisplatin, and anti-PD-1 therapy produced promising results for the use of primary anti-PD-1 and chemotherapy to treat nasopharynx cancer. In addition, a significant pathologic response was found in resectable oral cavity cancer patients when subject to neoadjuvant immunotherapy, potentiating the use of adjuvant therapy in oral cavity cancer treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.